{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:36:10Z","timestamp":1790681770626,"version":"4.1.0"},"reference-count":102,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Henry Schueler Foundation"},{"name":"Save Our Sick Kids Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Treatments for emerging and rare invasive fungal diseases (IFDs) represent a critical unmet medical need. For IFDs that occur less frequently than invasive aspergillosis, such as mucormycosis, hyalohyphomycosis, and phaeohyphomycosis, randomized controlled clinical trials are impractical and unlikely to meet urgent public health needs. Understanding regulatory approaches for approval of drugs for rare cancers and rare metabolic diseases could help meet the challenges of studying drugs for rare IFDs. A single-arm, controlled clinical trial with a high-quality external control(s), with confirmatory evidence from nonclinical studies, including pharmacokinetic\/pharmacodynamic data in predictive animal models of the disease may support findings of effectiveness of new drugs and biologics. Control populations may include historical controls from published literature, patient registries, and\/or contemporaneous external control groups. Continuous engagement among clinicians, industrial sponsors, and regulatory agencies to develop consensus on trial design and innovative development pathways for emergent and rare invasive fungal diseases is important.<\/jats:p>","DOI":"10.1093\/ofid\/ofae257","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T12:01:35Z","timestamp":1718625695000},"source":"Crossref","is-referenced-by-count":12,"title":["Meeting the Therapeutic Challenges of Emergent and Rare Invasive Fungal Diseases Through Novel Clinical Trial Designs"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7078-9778","authenticated-orcid":false,"given":"Thomas J","family":"Walsh","sequence":"first","affiliation":[{"name":"Center for Innovative Therapeutics and Diagnostics , Office of the Director ( citdx.org ), Richmond, Virginia, USA"},{"name":"Departments of Medicine and of Microbiology & Immunology, University of Maryland School of Medicine , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,6,17]]},"reference":[{"key":"2024061712012841900_ofae257-B1","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"2024061712012841900_ofae257-B2","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0140-6736(21)00219-1","article-title":"Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial","volume":"397","author":"Maertens","year":"2021","journal-title":"Lancet"},{"key":"2024061712012841900_ofae257-B3"},{"key":"2024061712012841900_ofae257-B4","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1183\/16000617.0017-2016","article-title":"Why we should care about ultra-rare disease?","volume":"25","author":"Harari","year":"2016","journal-title":"Eur Respir Rev"},{"key":"2024061712012841900_ofae257-B5","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1177\/2042098618792502","article-title":"Pharmacovigilance of medicines for rare and ultrarare diseases","volume":"9","author":"Sardella","year":"2018","journal-title":"Ther Adv Drug Saf"},{"key":"2024061712012841900_ofae257-B6","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.cmi.2016.01.011","article-title":"Emerging infections caused by non-Aspergillus filamentous fungi","volume":"22","author":"Douglas","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"2024061712012841900_ofae257-B7","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.12688\/f1000research.11124.1","article-title":"Rare fungal infectious agents: a lurking enemy","volume":"6","author":"Skiada","year":"2017","journal-title":"F1000Res"},{"key":"2024061712012841900_ofae257-B8","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.cmi.2023.03.008","article-title":"COVID-19-associated mucormycosis: a systematic review and meta-analysis of 958 cases","volume":"29","author":"\u00d6zbek","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"2024061712012841900_ofae257-B9","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3390\/jof5030057","article-title":"Necrotizing mucormycosis of wounds following combat injuries, natural disasters, burns, and other trauma","volume":"5","author":"Walsh","year":"2019","journal-title":"J Fungi (Basel)"},{"key":"2024061712012841900_ofae257-B10","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.3201\/eid1710.110087","article-title":"Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001\u20132006","volume":"17","author":"Park","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"2024061712012841900_ofae257-B11","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/clinids\/27.5.1138","article-title":"The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992\u20131993: results of population-based laboratory active surveillance","volume":"27","author":"Rees","year":"1998","journal-title":"Clin Infect Dis"},{"key":"2024061712012841900_ofae257-B12","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1086\/651262","article-title":"Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET)","volume":"50","author":"Pappas","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2024061712012841900_ofae257-B13","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1086\/651263","article-title":"Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001\u20132006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database","volume":"50","author":"Kontoyiannis","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2024061712012841900_ofae257-B14","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1086\/383319","article-title":"Fusarium infection in hematopoietic stem cell transplant recipients","volume":"38","author":"Nucci","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2024061712012841900_ofae257-B15","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1086\/375822","article-title":"Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi","volume":"37","author":"Husain","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2024061712012841900_ofae257-B16","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.ijantimicag.2018.08.005","article-title":"Rare mould infections caused by Mucorales, Lomentospora prolificans and Fusarium, in San Diego, CA: the role of antifungal combination therapy","volume":"52","author":"Jenks","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2024061712012841900_ofae257-B17","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1086\/509579","article-title":"Scedosporium infection in a tertiary care cancer center: a review of 25 cases from 1989\u20132006","volume":"43","author":"Lamaris","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2024061712012841900_ofae257-B18","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.15585\/mmwr.mm6544e1","article-title":"Investigation of the first seven reported cases of Candida auris, a globally emerging invasive, multidrug-resistant fungus\u2014United States, May 2013-August 2016","volume":"65","author":"Vallabhaneni","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024061712012841900_ofae257-B19","doi-asserted-by":"crossref","first-page":"6","DOI":"10.15585\/mmwr.mm6901a2","article-title":"Candida auris isolates resistant to three classes of antifungal medications\u2014New York, 2019","volume":"69","author":"Ostrowsky","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024061712012841900_ofae257-B20","doi-asserted-by":"crossref","first-page":"489","DOI":"10.7326\/M22-3469","article-title":"Worsening spread of Candida auris in the United States, 2019 to 2021","volume":"176","author":"Lyman","year":"2023","journal-title":"Ann Intern Med"},{"key":"2024061712012841900_ofae257-B21","doi-asserted-by":"crossref","first-page":"e0005322","DOI":"10.1128\/aac.00053-22","article-title":"Candida auris pan-resistant to four major classes of antifungal agents","volume":"66","author":"Jacobs","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2024061712012841900_ofae257-B22","doi-asserted-by":"crossref","first-page":"e246","DOI":"10.1016\/S1473-3099(20)30784-2","article-title":"Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology [published correction occurs in","volume":"21","author":"Hoenigl","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2024061712012841900_ofae257-B23","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":". Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium","volume":"19","author":"Cornely","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2024061712012841900_ofae257-B24","doi-asserted-by":"crossref","first-page":"e375","DOI":"10.1016\/S1473-3099(21)00203-6","article-title":"Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM [published correction occurs in","volume":"21","author":"Chen","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2024061712012841900_ofae257-B25","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1086\/376634","article-title":"Amphotericin B: time for a new \u201cgold standard.\u201d","volume":"37","author":"Ostrosky-Zeichner","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2024061712012841900_ofae257-B26","author":"National Library of Medicine"},{"key":"2024061712012841900_ofae257-B27","author":"National Library of Medicine"},{"key":"2024061712012841900_ofae257-B28","author":"National Library of Medicine"},{"key":"2024061712012841900_ofae257-B29","author":"National Library of Medicine","year":"2022"},{"key":"2024061712012841900_ofae257-B30","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2024061712012841900_ofae257-B31","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/432579","article-title":"Epidemiology and outcome of zygomycosis: a review of 929 reported cases","volume":"41","author":"Roden","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2024061712012841900_ofae257-B32","author":"US Food and Drug Administration"},{"key":"2024061712012841900_ofae257-B33","doi-asserted-by":"crossref","first-page":"S474","DOI":"10.1093\/infdis\/jix130","article-title":"Novel agents and drug targets to meet the challenges of resistant fungi","volume":"216","author":"McCarthy","year":"2017","journal-title":"J Infect Dis"},{"key":"2024061712012841900_ofae257-B34","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s40265-021-01611-0","article-title":"The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin","volume":"81","author":"Hoenigl","year":"2021","journal-title":"Drugs"},{"key":"2024061712012841900_ofae257-B35","doi-asserted-by":"crossref","first-page":"507","DOI":"10.12688\/f1000research.28327.1","article-title":"Novel antifungal agents in clinical trials","volume":"10","author":"Jacobs","year":"2021","journal-title":"F1000Res"},{"key":"2024061712012841900_ofae257-B36","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/cid\/ciab1070","article-title":"Investigational antifungal agents for invasive mycoses: a clinical perspective","volume":"75","author":"Lamoth","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2024061712012841900_ofae257-B37","author":"US Food and Drug Administration"},{"key":"2024061712012841900_ofae257-B38","author":"US Food and Drug Administration"},{"key":"2024061712012841900_ofae257-B39","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1158\/1078-0432.CCR-12-1135","article-title":"Rare cancer trial design: lessons from FDA approvals","volume":"18","author":"Gaddipati","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2024061712012841900_ofae257-B40","author":"US Food and Drug Administration"},{"key":"2024061712012841900_ofae257-B41","author":"US Food and Drug Administration"},{"key":"2024061712012841900_ofae257-B42","author":"US Food and Drug Administration"},{"key":"2024061712012841900_ofae257-B43","first-page":"e49","article-title":"In brief: uridine triacetate (Xuriden) for hereditary orotic aciduria","volume":"58","year":"2016","journal-title":"Med Lett Drugs Ther"},{"key":"2024061712012841900_ofae257-B44","first-page":"562","article-title":"Pharmaceutical approval update","volume":"42","author":"Kaufman","year":"2017","journal-title":"P T"},{"key":"2024061712012841900_ofae257-B45","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40265-020-01464-z","article-title":"Lonafarnib: first approval [published correction occurs in","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"2024061712012841900_ofae257-B46","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1001\/jama.2018.3264","article-title":"Association of lonafarnib treatment vs no treatment with mortality rate in patients with Hutchinson-Gilford progeria syndrome","volume":"319","author":"Gordon","year":"2018","journal-title":"JAMA"},{"key":"2024061712012841900_ofae257-B47","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/S0140-6736(15)00124-5","article-title":"Efficacy and safety of cyclic pyranopterin monophosphate substitution in severe molybdenum cofactor deficiency type A: a prospective cohort study","volume":"386","author":"Schwahn","year":"2015","journal-title":"Lancet"},{"key":"2024061712012841900_ofae257-B48","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s40265-021-01520-2","article-title":"Fosdenopterin: first approval","volume":"81","author":"Kang","year":"2021","journal-title":"Drugs"},{"key":"2024061712012841900_ofae257-B49","author":"U.S. Food and Drug Administration","year":"2019"},{"key":"2024061712012841900_ofae257-B50","article-title":"Rare diseases: common issues in drug development\u2014guidance for industry, January 2019","author":"U.S. Food and Drug Administration"},{"key":"2024061712012841900_ofae257-B51","author":"U.S. Food and Drug Administration"},{"key":"2024061712012841900_ofae257-B52","author":"U.S. Food and Drug Administration"},{"key":"2024061712012841900_ofae257-B53","author":"Project Data Sphere"},{"key":"2024061712012841900_ofae257-B54","author":"CDC Childhood Cancer STAR Project"},{"key":"2024061712012841900_ofae257-B55","author":"Cystic Fibrosis Foundation"},{"key":"2024061712012841900_ofae257-B56","author":"National Center for Advancing Translational Sciences"},{"key":"2024061712012841900_ofae257-B57","author":"Children's Hospital of Pittsburgh"},{"key":"2024061712012841900_ofae257-B58","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1007\/s10875-020-00844-0","article-title":"The Italian registry for primary immunodeficiencies (Italian Primary Immunodeficiency Network; IPINet): twenty years of experience (1999\u20132019)","volume":"40","author":"Lougaris","year":"2020","journal-title":"J Clin Immunol"},{"key":"2024061712012841900_ofae257-B59"},{"key":"2024061712012841900_ofae257-B60","author":"ECMM-ISHAM Working Group on Zygomycosis"},{"key":"2024061712012841900_ofae257-B61","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1111\/j.1469-0691.2010.03456.x","article-title":". Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007","volume":"17","author":"Skiada","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"2024061712012841900_ofae257-B62","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.diagmicrobio.2012.06.012","article-title":"The PATH (Prospective Antifungal Therapy) Alliance\u00ae registry and invasive fungal infections: update 2012","volume":"73","author":"Azie","year":"2012","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2024061712012841900_ofae257-B63","first-page":"269","article-title":"Epidemiological features of invasive mold infections among solid organ transplant recipients: PATH Alliance\u00ae registry analysis","volume":"55","author":"Husain","year":"2017","journal-title":"Med Mycol"},{"key":"2024061712012841900_ofae257-B64","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/myc.12212","article-title":"Treatment and outcomes of invasive fusariosis: review of 65 cases from the PATH Alliance (\u00ae) registry","volume":"57","author":"Horn","year":"2014","journal-title":"Mycoses"},{"key":"2024061712012841900_ofae257-B65","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.diagmicrobio.2007.06.008","article-title":"Presentation of the PATH Alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections","volume":"59","author":"Horn","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2024061712012841900_ofae257-B66","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1086\/595846","article-title":"Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry","volume":"48","author":"Neofytos","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2024061712012841900_ofae257-B67","doi-asserted-by":"crossref","first-page":"ofx200","DOI":"10.1093\/ofid\/ofx200","article-title":"A mycoses study group international prospective study of phaeohyphomycosis: an analysis of 99 proven\/probable cases","volume":"4","author":"Revankar","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2024061712012841900_ofae257-B68","first-page":"1609","article-title":"Multicenter registry of patients receiving systemic mold-active triazoles for the management of invasive fungal infections","volume":"11","author":"Ostrosky-Zeichner","year":"2022","journal-title":"Infect Dis Ther"},{"key":"2024061712012841900_ofae257-B69","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/myc.13412","article-title":"Systemic antifungal therapy with isavuconazonium sulfate or other agents in adults with invasive mucormycosis or invasive aspergillosis (non-fumigatus): a multicentre, non-interventional registry study","volume":"65","author":"Thompson","year":"2022","journal-title":"Mycoses"},{"key":"2024061712012841900_ofae257-B70","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl J Med"},{"key":"2024061712012841900_ofae257-B71","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1128\/AAC.02301-13","article-title":"Isavuconazole therapy protects immunosuppressed mice from mucormycosis","volume":"58","author":"Luo","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2024061712012841900_ofae257-B72","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1128\/AAC.01222-09","article-title":"Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis","volume":"54","author":"Lewis","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2024061712012841900_ofae257-B73","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/978-1-4939-7104-6_18","article-title":"Endpoint assessment in rabbit models of invasive pulmonary aspergillosis and mucormycosis","volume":"1625","author":"Petraitis","year":"2017","journal-title":"Methods Mol Biol"},{"key":"2024061712012841900_ofae257-B74","doi-asserted-by":"crossref","first-page":"e486","DOI":"10.1111\/j.1439-0507.2010.01958.x","article-title":"Antifungal activity of posaconazole and granulocyte colony-stimulating factor in the treatment of disseminated zygomycosis (mucormycosis) in a neutropaenic murine model","volume":"54","author":"Saoulidis","year":"2011","journal-title":"Mycoses"},{"key":"2024061712012841900_ofae257-B75","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1093\/jac\/dku224","article-title":"Assessing micafungin\/triazole combinations for the treatment of invasive scedosporiosis due to Scedosporium apiospermum and Scedosporium boydii","volume":"69","author":"Lackner","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2024061712012841900_ofae257-B76","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/jac\/49.3.525","article-title":"Liposomal amphotericin B and granulocyte colony-stimulating factor therapy in a murine model of invasive infection by Scedosporium prolificans","volume":"49","author":"Ortoneda","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"2024061712012841900_ofae257-B77","doi-asserted-by":"crossref","first-page":"e0043421","DOI":"10.1128\/AAC.00434-21","article-title":"In vivo efficacy of olorofim against systemic scedosporiosis and lomentosporiosis","volume":"65","author":"Seyedmousavi","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2024061712012841900_ofae257-B78","doi-asserted-by":"crossref","first-page":"e01735-19","DOI":"10.1128\/AAC.01735-19","article-title":"Fosmanogepix (APX001) is effective in the treatment of immunocompromised mice infected with invasive pulmonary scedosporiosis or disseminated fusariosis","volume":"64","author":"Alkhazraji","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2024061712012841900_ofae257-B79","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s11046-013-9687-3","article-title":"Murine model of disseminated fusariosis: evaluation of the fungal burden by traditional CFU and quantitative PCR","volume":"176","author":"Gonz\u00e1lez","year":"2013","journal-title":"Mycopathologia"},{"key":"2024061712012841900_ofae257-B80","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ijantimicag.2010.08.008","article-title":"Treatment of murine Fusarium verticillioides infection with liposomal amphotericin B plus terbinafine","volume":"37","author":"Ru\u00edz-Cendoya","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"2024061712012841900_ofae257-B81","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1128\/iai.60.8.3339-3344.1992","article-title":"A novel murine model of disseminated trichosporonosis","volume":"60","author":"Gokaslan","year":"1992","journal-title":"Infect Immun"},{"key":"2024061712012841900_ofae257-B82","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/BF01103609","article-title":"Disseminated trichosporonosis in a neutropenic murine model","volume":"122","author":"Hospenthal","year":"1993","journal-title":"Mycopathologia"},{"key":"2024061712012841900_ofae257-B83","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/infdis\/166.1.121","article-title":"Experimental trichosporon infection in persistently granulocytopenic rabbits: implications for pathogenesis, diagnosis, and treatment of an emerging opportunistic mycosis","volume":"166","author":"Walsh","year":"1992","journal-title":"J Infect Dis"},{"key":"2024061712012841900_ofae257-B84","doi-asserted-by":"crossref","first-page":"e0054921","DOI":"10.1128\/AAC.00549-21","article-title":"Efficacy of voriconazole, isavuconazole, fluconazole, and anidulafungin in the treatment of emerging Candida auris using an immunocompromised murine model of disseminated candidiasis","volume":"65","author":"Gamal","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2024061712012841900_ofae257-B85","doi-asserted-by":"crossref","first-page":"e00854-20","DOI":"10.1128\/AAC.00854-20","article-title":"Efficacy of ibrexafungerp (SCY-078) against Candida auris in an in vivo Guinea pig cutaneous infection model","volume":"64","author":"Ghannoum","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2024061712012841900_ofae257-B86","doi-asserted-by":"crossref","first-page":"e00791-17","DOI":"10.1128\/AAC.00791-17","article-title":"Pharmacodynamic optimization for treatment of invasive Candida auris infection","volume":"61","author":"Lepak","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2024061712012841900_ofae257-B87","doi-asserted-by":"crossref","first-page":"2020-9","DOI":"10.1056\/NEJMoa021585","article-title":"Comparison of caspofungin and amphotericin B for invasive candidiasis","volume":"347","author":"Mora-Duarte","year":"2002","journal-title":"N Engl J Med"},{"key":"2024061712012841900_ofae257-B88","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1056\/NEJMoa066906","article-title":"Anidulafungin versus fluconazole for invasive candidiasis","volume":"356","author":"Reboli","year":"2007","journal-title":"N Engl J Med"},{"key":"2024061712012841900_ofae257-B89","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/cid\/civ495","article-title":"Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR) [published correction occurs in","volume":"61","author":"Evans","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2024061712012841900_ofae257-B90","author":"National Library of Medicine"},{"key":"2024061712012841900_ofae257-B91","doi-asserted-by":"crossref","first-page":"i19","DOI":"10.1093\/jac\/dkx030","article-title":"Early diagnosis of invasive mould infections and disease","volume":"72","author":"Lamoth","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2024061712012841900_ofae257-B92","doi-asserted-by":"crossref","first-page":"e00924","DOI":"10.1128\/AAC.00924-20","article-title":"Screening repurposing libraries for identification of drugs with novel antifungal activity","volume":"64","author":"Wall","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2024061712012841900_ofae257-B93","doi-asserted-by":"crossref","first-page":"5259","DOI":"10.1007\/s00253-021-11407-7","article-title":"Drug repurposing strategies in the development of potential antifungal agents","volume":"105","author":"Zhang","year":"2021","journal-title":"Appl Microbiol Biotechnol"},{"key":"2024061712012841900_ofae257-B94","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/myc.13477","article-title":"Drug repurposing against Candida auris: a systematic review","volume":"65","author":"Izadi","year":"2022","journal-title":"Mycoses"},{"key":"2024061712012841900_ofae257-B95","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.3390\/jof9121166","article-title":"Miltefosine: a repurposing drug against Mucorales pathogens","volume":"9","author":"Xisto","year":"2023","journal-title":"J Fungi (Basel)"},{"key":"2024061712012841900_ofae257-B96","doi-asserted-by":"crossref","first-page":"698662","DOI":"10.3389\/fcimb.2021.698662","article-title":"Miltefosine against Scedosporium and Lomentospora species: antifungal activity and its effects on fungal cells","volume":"11","author":"Rollin-Pinheiro","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"2024061712012841900_ofae257-B97","doi-asserted-by":"crossref","first-page":"e071108","DOI":"10.1136\/bmj-2022-071108","article-title":"Target trial emulation: applying principles of randomised trials to observational studies","volume":"378","author":"Matthews","year":"2022","journal-title":"BMJ"},{"key":"2024061712012841900_ofae257-B98","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/cid\/ciaa615","article-title":"Withholding primary pneumocystis pneumonia prophylaxis in virologically suppressed patients with human immunodeficiency virus: an emulation of a pragmatic trial in COHERE","volume":"73","author":"Atkinson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024061712012841900_ofae257-B99","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/cid\/ciad122","article-title":"Early antiretroviral therapy not associated with higher cryptococcal meningitis mortality in people with human immunodeficiency virus in high-income countries: an international collaborative cohort study","volume":"77","author":"Ingle","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2024061712012841900_ofae257-B100","article-title":"Shared vision for improving outcomes for serious fungal diseases: report of a patient\/provider summit","volume":"ofae226","author":"Purdie","journal-title":"Open Forum Infect Dis"},{"key":"2024061712012841900_ofae257-B101","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/cid\/ciad195","article-title":"Food and Drug Administration public workshop summary\u2014development considerations of antifungal drugs to address unmet medical need","volume":"77","author":"Yasinskaya","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2024061712012841900_ofae257-B102","author":"US Food and Drug Administration"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/6\/ofae257\/58234260\/ofae257.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/6\/ofae257\/58234260\/ofae257.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T12:02:23Z","timestamp":1718625743000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofae257\/7693432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":102,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofae257","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6]]},"published":{"date-parts":[[2024,6]]},"article-number":"ofae257"}}